Evidence map›Paper›PMID 27648302›Full record

ArticleCell death discovery2016

Proteolytic inactivation of nuclear alarmin high-mobility group box 1 by complement protease C1s during apoptosis.

J G Yeo, J Leong, T Arkachaisri, Y Cai, B H D Teo, J H T Tan, L Das, J Lu

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05193591 (Evaluation of Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in the Pathogenesis for Patients With Systemic Lupus Erythematosus), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05193591 recruitingnot on this mapstarted 2022, after this paper: background citation

Evaluation of Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in the Pathogenesis for Patients With Systemic Lupus Erythematosus (SLE)

TypeobservationalSponsorUniversity Hospital, GrenobleRan2022 to 2025Enrolled30ConditionsLupus Erythematosus, SystemicArmsAutoantibodies evaluation in lupus
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Two Different MissenseFrontiers in immunology · 2019
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Complement the cell death.Cell death & disease · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

J G YeoDepartment of Microbiology and Immunology, Immunology Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Medicine, KK Women's and Children's Hospital, Singapore; SingHealth Translational Immunology and Inflammation Center, Singapore Health Services, Singapore.
J LeongDivision of Medicine, KK Women's and Children's Hospital , Singapore.
T ArkachaisriRheumatology and Immunology Service, Department of Pediatric Subspecialities, KK Women's and Children's Hospital, Singapore; Duke-National University of Singapore Medical School, Singapore.
Y CaiDepartment of Microbiology and Immunology, Immunology Program, Yong Loo Lin School of Medicine, National University of Singapore , Singapore.
B H D TeoDepartment of Microbiology and Immunology, Immunology Program, Yong Loo Lin School of Medicine, National University of Singapore , Singapore.
J H T TanRheumatology and Immunology Service, Department of Pediatric Subspecialities, KK Women's and Children's Hospital , Singapore.
L DasRheumatology and Immunology Service, Department of Pediatric Subspecialities, KK Women's and Children's Hospital , Singapore.
J LuDepartment of Microbiology and Immunology, Immunology Program, Yong Loo Lin School of Medicine, National University of Singapore , Singapore.
KK Women's and Children's Hospital · SGNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective clearance of apoptotic cells by phagocytes prevents the release of intracellular alarmins and manifestation of autoimmunity. This prompt efferocytosis is complemented by intracellular proteolytic degradation that occurs within the apoptotic cells and in the efferosome of the phagocytes. Although the role of extracellular proteases in apoptotic cells clearance is unknown, the strong association of congenital C1s deficiency with Systemic Lupus Erythematosus highlights the protective nature that this extracellular protease has against autoimmunity. The archetypical role of serine protease C1s as the catalytic arm of C1 complex (C1qC1r2C1s2) involve in the propagation of the classical complement pathway could not provide the biological basis for this association. However, a recent observation of the ability of C1 complex to cleave a spectrum of intracellular cryptic targets exposed during apoptosis provides a valuable insight to the underlying protective mechanism. High-mobility group box 1 (HMGB1), an intracellular alarmin that is capable of inducing the formation of antinuclear autoantibodies and causes lupus-like conditions in mice, is identified as a novel potential target by bioinformatics analysis. This is verified experimentally with C1s, both in its purified and physiological form as C1 complex, cleaving HMGB1 into defined fragments of 19 and 12 kDa. This cleavage diminishes HMGB1 ability to enhance lipopolysaccharide mediated pro-inflammatory cytokines production from monocytes, macrophages and dendritic cells. Further mass spectrometric analysis of the C1 complex treated apoptotic cellular proteins demonstrated additional C1s substrates and revealed the complementary role of C1s in apoptotic cells clearance through the proteolytic cleavage of intracellular alarmins and autoantigens. C1 complex may have evolved as, besides the bacteriolytic arm of antibodies in which it activates the complement cascade, a tissue renewal mechanism that reduces the immunogenicity of apoptotic tissue debris and decreases the likelihood of autoimmunity.

Identifiers

PMID27648302
PMCPMC5018544
OpenAlexW2519937762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.